Department of Pediatric Neurology, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey.
Faculty of Medicine, Biostatistics and Medical Informatics, Süleyman Demirel University, Isparta, Turkey.
Pediatr Int. 2021 Nov;63(11):1344-1350. doi: 10.1111/ped.14685. Epub 2021 Oct 28.
Aim of this study was to analyze the effect of iron therapy in children with breath-holding spells, irrespective of their hemoglobin level.
All of the children were evaluated in terms of age, sex, age at onset of the attack, attack frequency, type of breath-holding spell, family pedigree, laboratory values. All enrolled patients were given iron at the dose of 4 mg/kg/day as a single daily dose for 3 months. Patients were called for follow-up appointments 1 and 3 months after the initiation of treatment to record the frequency and severity of spells.
The mean age of the patients was 12.50 ± 9.51 months. Patients were divided into two groups according to the hemoglobin level. The frequency of anemia in children with spells was recorded as 27%. Out of 100 patients treated with iron, 43% showed complete remission at the end of 1 month. At the end of the 3 months, percentage of complete responders increased to 80%. After three-month of iron treatment, 96.2% of the anemic and 73.97% of the non-anemic patients were spell-free. Eight children had mild adverse effects after iron therapy that did not require dose modification.
This study confirmed that iron therapy reduces spell frequency regardless of anemia in all breath-holding spells. A three-month empiric iron therapy should be offered to all children with spells.
本研究旨在分析铁治疗对屏气发作患儿的影响，而不论其血红蛋白水平如何。
所有患儿均进行年龄、性别、发作起始年龄、发作频率、屏气发作类型、家族病史、实验室检查评估。所有入组患儿均给予铁剂 4mg/kg/天，单次剂量，疗程 3 个月。治疗开始后 1 个月和 3 个月时进行随访，记录发作频率和严重程度。
患儿的平均年龄为 12.50±9.51 个月。根据血红蛋白水平将患儿分为两组。发作患儿中贫血的发生率为 27%。100 例接受铁治疗的患儿中，43%在 1 个月时完全缓解。3 个月时，完全缓解率增加至 80%。铁治疗 3 个月后，贫血患儿中 96.2%、非贫血患儿中 73.97%无发作。8 例患儿在铁治疗后出现轻微不良反应，但无需调整剂量。
本研究证实，铁治疗可降低所有屏气发作患儿的发作频率，而与贫血无关。应给予所有发作患儿 3 个月的经验性铁治疗。
